SCHEMBL2173936

SCHEMBL2173936

CC(C)(C)OC(=O)NCCC(O)c1cccc(NCC2(O)CCCC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.40
NPFFR1 Q9GZQ6 1/20 0.38
NPFFR2 Q9Y5X5 1/20 0.38
DRD2 P14416 6/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
MALT1 Q9UDY8 1/20 0.36
UTS2R Q9UKP6 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
NQO2 P16083 1/20 0.35
NAMPT P43490 1/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
BRD4 O60885 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3124912 0.99 IDO1 (0.39) IDO1NPFFR1NPFFR2DRD2CYP3A4
SCHEMBL2151176 0.86 IDO1 (0.38) IDO1NPFFR1NPFFR2DRD2CYP3A4
SCHEMBL3131901 0.83 ROCK2 (0.36) CYP3A4CYP2C19KMT2A
SCHEMBL2209184 0.82 PDK2 (0.39) DRD2CYP3A4CYP2C19NQO2
SCHEMBL1725320 0.82 MALT1 (0.36) IDO1DRD2CYP3A4CYP2C19MALT1
SCHEMBL1726496 0.81 CYP3A4 (0.35) IDO1DRD2CYP3A4CYP2C19MALT1
SCHEMBL13323791 0.80 OPRK1 (0.42) IDO1DRD2CA1CA2
SCHEMBL611790 0.80 CYP3A4 (0.40) IDO1NPFFR1NPFFR2DRD2CYP3A4
SCHEMBL2178511 0.80 CA1 (0.40) NPFFR1NPFFR2DRD2CYP3A4CYP2C19
SCHEMBL2167735 0.80 CA1 (0.42) IDO1CA1CA2MALT1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145198-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2016-05-26 US disclosed
US-9193669-B2 Compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2015-11-24 US disclosed
US-20140228443-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. (US) 2014-08-14 US disclosed
US-8674137-B2 Compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2014-03-18 US disclosed
EP-2340242-A2 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS Acucela, Inc. (US) 2011-07-06 EP disclosed
US-20100113539-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2010-05-06 US disclosed
WO-2010048332-A2 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113539-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, ALDH1A2 IDO1 3948/4885NPFFR1 3994/4885NPFFR2 4217/4885
US-20160145198-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, ALDH1A2 IDO1 3948/4885NPFFR1 3994/4885NPFFR2 4217/4885
US-20140228443-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, ALDH1A2 IDO1 3948/4885NPFFR1 3994/4885NPFFR2 4217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.